Should You Buy Aprea Therapeutics, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Aprea Therapeutics, Inc. (APRE) scores 4.8/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $0.86, our multi-model valuation analyzes whether the market has already discounted these weaknesses.
The short answer: 0 of 1 CirclFi valuation models project upside for Aprea Therapeutics, Inc. (APRE) at $0.86 — the model consensus leans bearish, with a Quality Score of 4.8/10 and Value-Trap risk of 51/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Aprea Therapeutics, Inc. (APRE) in 2026?
What Is the Bull Case vs the Bear Case for Aprea Therapeutics, Inc. (APRE)?
| Bull case | Bear case — $0.48 target (-44.6%) |
|---|---|
| No active model projects meaningful upside for APRE at $0.86. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. | According to the CirclFi Quality of Company (QOC) framework, Aprea Therapeutics, Inc.'s score of 4.8/10 signals fundamental weaknesses that could undermine the investment thesis. |
| According to the CirclFi Value Trap algorithm, the stock shows moderate caution signals, meaning investors should verify that apparent undervaluation isn't masking declining business quality. | |
| According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $0.48 (-44.6%), suggesting that the market price embeds overly optimistic growth assumptions. | |
| Industry headwind: manufacturing scale-up challenges represents a meaningful risk for Aprea Therapeutics, Inc. and its Biotechnology peers. |
How Does APRE Compare to Its Biotechnology Peers?
Valuation data pages: RAPP · DMRA · KTTA · NNVC · REPL · FLNA · MTNB · GMAB · OBIO · EXEL · INCY
Which Other Stocks Score Like APRE on Quality?
Closest companies to APRE’s Quality of Company score of 4.8/10, across all industries.
- WORX — SCWorx Corp (QOC 4.8) · analysis
- VSEE — VSee Health, Inc. (QOC 4.8) · analysis
- HTOO — Fusion Fuel Green PLC (QOC 4.8) · analysis
- KREF — KKR Real Estate Finance Trust Inc. (QOC 4.8) · analysis
- MGRX — Mangoceuticals, Inc. (QOC 4.8) · analysis
- WYTC — WYTEC INTERNATIONAL INC (QOC 4.8) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Biotechnology Screens Does APRE Appear In?
So Is Aprea Therapeutics, Inc. (APRE) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on Aprea Therapeutics, Inc. at $0.86. 1/1 models flag overvaluation, median fair value sits at $0.48 (-44.6%), and the risk-reward profile appears unfavorable. Quality at 4.8/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Aprea Therapeutics, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About APRE Stock?
Should I buy APRE stock right now?
Based on CirclFi's multi-model analysis, 0 of 1 models see upside for APRE at $0.86. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Aprea Therapeutics, Inc.?
Key risks include: an elevated Value Trap score of 51/100, suggesting apparent undervaluation may mask deteriorating fundamentals; a below-average Quality Score of 4.8/10, indicating fundamental weakness; limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does APRE compare to its competitors?
Among Biotechnology peers, APRE holds a Quality Score of 4.8/10. Comparable companies include RAPP (QOC 4.8), DMRA (QOC 4.8), KTTA (QOC 4.8). The relative ranking helps investors identify whether APRE offers better fundamental quality than alternatives in the same sector.
Is APRE a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. APRE's Quality Score of 4.8/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.
What price should I buy APRE at?
CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $0.48 to $0.48. At $0.86, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for APRE.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad